This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
The documentation on substitution between formats is better than this thread and I say that as someone who has posted in the thread.
That is a cleaner way of putting what I was circling around.
Where I part company with post #29, and it is a narrow parting.
Allocation and rationing: during severe shortages, suppliers might ration allocation to prescribers. Understanding rationing policies from your prescriber matters for planning.
Written quickly, so the reasoning may be tighter than the wording.
Supply interruptions: official shortage notices are published by regulatory agencies. That is the correct primary source rather than pharmacy rumors or forum discussion.
Noting that the question and the thing people usually mean by it are different.
International supply chains: a shortage in one country does not mean shortage in another. That is why ordering from multiple suppliers before a shortage gets bad is prudent if you can.
Two people can read the same figure differently here and both be reasonable.
Second-hand on substitution between formats, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.
Post #33 put the caveat in the right place and I want to underline it.
Something worth flagging about substitution between formats: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a coincidence.
Building on post #37 rather than restating it.
Dose hold versus tapering: if a temporary shortage forces a gap, holding your dose and resuming when supply returns is different from gradually tapering. The two are different decisions.
On balance I think that is right, and I would not bet much on it.
No disagreement from me. Posting only so the question does not look ignored.
Compounding during shortages: some jurisdictions allow pharmacy compounding when a marketed product is in shortage. That permission is jurisdiction-specific and time-limited (usually for the duration of the shortage).
None of the above is medical advice and I am not qualified to give any.
Shortage predictions: regulators and suppliers issue shortage alerts before they become acute. Checking the regulatory website for shortages gives you advance notice.
I keep a log of this specifically because memory is unreliable about it.
Post #40 describes the usual case. This is about the unusual one.
Substitution between formats is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
Confirming post #42 from a second method, which matters more than confirming it from a second person.
Allocation and rationing: during severe shortages, suppliers might ration allocation to prescribers. Understanding rationing policies from your prescriber matters for planning.
I would want the raw data before agreeing with my own summary of it.
Picking up post #42: that is the part I would want checked first.
Manufacturer allocation decisions during a shortage are commercial and are rarely explained, which is frustrating and is not evidence of anything.
The short answer was in the first line; everything after is the working.
On post #45 — agreed on the reasoning, with one qualification.
A shortage of one presentation is not a shortage of all of them, and the published notices are specific about which.
I have seen it go both ways, which is why I hedge.
Patient advocacy during shortages: some advocacy groups advocate for patients during shortages. Knowing who they are and following their communication is useful.
This follows post #46 rather than contradicting it.
Nothing here is medical advice, and decisions about what to do during a supply interruption belong with a prescriber.
I am describing what is, rather than arguing for what should be.
The published shortage register maintained by the national regulator is the authoritative source here, and it is updated far more often than any thread.
Switching presentation or strength during a shortage is a prescribing decision rather than a substitution anybody should improvise.
Both are useful and different. The notice tells you the national position; the account tells you what is happening on the ground.
I checked the source rather than the summary, and they differ.
Worth separating two things that post #51 runs together.
A note on scope: what I am saying about substitution between formats applies to the case in the first post and I would not extend it further without checking.
Supply interruptions: official shortage notices are published by regulatory agencies. That is the correct primary source rather than pharmacy rumors or forum discussion.
Pharmacy-level availability varies enormously during a shortage, so two honest accounts from the same city can be opposite.
Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are how long the gap will be and how that affects your condition. Discussing with your clinician is prudent if the gap is weeks or longer.
Taking post #59 at face value and following it one step further.
Shortage-driven price movement is real and is a separate question from availability.
The conclusion is tentative; the arithmetic underneath it is not.